In clinical studies, the application of Evolocumab or Alirocumab was also demonstrated to enhance the anti-tumor effects of anti-PD-1 therapy on several neoplasms, even in patients with cancers with resistance to immune checkpoint therapy [16]. Here, PDCD1 is linked to cancer.